BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Borsa Italiana 16:04:59 2024-07-05 EDT | ||
| 3.1 EUR | -3.43% |
|
| Current month | -11.46% | ||
| 1 month | -18.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 3.09 | -3.74% |
| 24-07-04 | 3.21 | +3.55% |
| 24-07-03 | 3.1 | -2.52% |
| 24-07-02 | 3.18 | -7.02% |
| 24-07-01 | 3.42 | -2.01% |
Real-time Borsa Italiana
Last update July 05, 2024 at 04:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S34620 | |
| ISIN | DE000SW7RC27 |
| Date issued | 2024-03-18 |
| Strike | 9,480 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.93 € |
|---|---|
| Lowest since issue | 1.158 € |
| Spread | 0.08 € |
| Spread % | 2.54% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
154.4
USD
Average target price
174.6
USD
Spread / Average Target
+13.10%
- Stock Market
- Certificates
- S34620 Certificat
